Back to search results
NCT05593588

Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency

Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatment
Avni Joshi
~20 participants
Updated 2026-06-30 on ClinicalTrials.gov
What's tested:FisetinPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in immunophenotyping of peripheral T lymphocytes
Measured over Baseline, 6 months

Conditions

Common Variable Immunodeficiency
Interstitial Lung Disease Due to Systemic Disease

Explore related trials

Common Variable ImmunodeficiencyInterstitial lung disease due to systemic disease

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Avni Joshi, MD, MS · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient must have received a diagnosis of CVID according to the international consensus document (ICON) at least 30 days before enrollment.
Physician diagnosis of possible GLILD associated with CVID.
IgA results.
Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile. (A negative pregnancy test for women whose menopausal status is determined by self-reported absence of menstrual periods in the past 12 months will be required within 72 hours prior to randomization).
Patient must be able and willing to comply with the requirements of this study protocol.

Exclusion

Unable or unwilling to give informed consent.
Presence of any condition that the Investigator or the subject's attending physician believes would put the subject at risk or would preclude the patient from successfully completing the trial.
Pregnant and/or lactating. Women of childbearing potential (WCBP) must have a negative pregnancy test within 72 hours prior to randomization.
Men who are unwilling to abstain from sex with WCBP or use an adequate method of contraception from the time of the first IP administration through 48 hours after the last IP administration.
Prisoners, institutionalized individuals, or others who may be considered vulnerable populations, such as individuals with dementia.
Patient currently hospitalized or under immediate consideration for hospitalization.
Current use of tobacco products or as per clinical judgement.
Current excessive caffeine intake (400 mg or more per day).

What this trial measures

  • Change in immunophenotyping of peripheral T lymphocytesBaseline, 6 months

    Measured by percentage of activated CD4+25+ T cells